Growth Metrics

Alnylam Pharmaceuticals (ALNY) R&D In Process (2014)

Alnylam Pharmaceuticals posted quarterly R&D In Process of $224.7 million for Q1 2014.

Alnylam Pharmaceuticals (ALNY) has 1 years of R&D In Process data on file, last reported at $224.7 million in Q1 2014.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D In Process (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 500,000.00
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 101.90 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Revolution Medicines 32.39 Bn 32.39 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2014 224.70 Mn